Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Name: Kaimen Rigor review — Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Item: Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Rating: 59
Author: Alpha1

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Read alongside

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

Read full text (PMC)

DOI

10.1038/s41591-026-04439-x

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b0bd815e-ed54-4cf8-a026-845a008ff135" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b0bd815e-ed54-4cf8-a026-845a008ff135/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4a4ce306bfa73364a3e5aa68d73762bdcb3ccc272c5823f3698370583b959f8f

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

Paper source

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 10, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Biggest issues

01Data and code not shared
highDisclosurereviewer-assessedFull detail
The data-availability statement is vague ('data are not available to share'), no sequencing accessions are provided for the exome data, and no analysis code is shared.
“Due to contractual agreements with sponsors, trial data are not available to share.”
Data availabilityFind in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper's core strengths are its rigorous randomized, double-blind, placebo-controlled parent trial with blinded adjudication, thorough demographic/biological-variable reporting, detailed statistical methods with assumption checks and plausible arithmetic, and conclusions that are transparently hypothesis-generating. Its main weaknesses are incomplete data/code availability (no sequencing accessions, no custom code), an under-identified investigational product (no dose/formulation), and a missing named regulatory-compliance framework, plus a minor main-text/figure inconsistency (missing minus sign in an ARR CI).

Full-text assessment by two independently sampled reviewer runs of the same model, which converged on six of eight dimension statuses; the one status divergence (data code availability warn vs fail) was resolved by weighing the data-availability statement as adequate, and minor sub-criterion divergences (randomization method detail, exact p-value practice) are noted in the relevant dimensions. Statistical verification recomputed 12 reported tests/effects consistently (threshold-only and exact/permutation p-values out of scope); citation check found 0 retracted and 0 not-found among 30 references; reproducibility links 4/4 live.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 12 tests: 12 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 6 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Implausibly large reported effectAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 2 warn · 1 fail

Prior work on SGLT2 inhibitors reducing HHF, the heritability of CMPs, and the prevalence/risk of P/LP variants is cited with specific cohorts (Spanish DCM cohort, UK Biobank). The rationale links the premise to the objective (testing dapagliflozin benefit in variant carriers) and the hypothesis follows. Limitations of the design are extensively addressed in the Discussion (small carrier number, post-hoc nature, absent imaging, generalizability).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific foundation is well established and the rationale follows clearly from prior evidence.

Evidence

“Sodium–glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin have been shown to prevent hospitalization for HF (HHF) across the spectrum of left ventricular ejection fraction (LVEF)”

Main, first two paragraphsFind in source

“Whether SGLT2 inhibitor treatment is of benefit in asymptomatic individuals with a CMP variant is not known.”

IntroductionFind in source

paraphrase[Discussion, final paragraphs]

“Paraphrase: The authors enumerate small carrier number (n=121), the post-hoc nature, absence of systematic cardiac imaging, short follow-up, and limited ancestry diversity as limitations.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific rationale grounded in prior work on SGLT2 inhibitors in heart failure and on the prognostic significance of cardiomyopathy variants.

Evidence

“Whether SGLT2 inhibitor treatment is of benefit in asymptomatic individuals with a CMP variant is not known.”

Main, paragraph 1Find in source

paraphrase[Main, paragraph 1]

“SGLT2 inhibitors such as dapagliflozin have been shown to prevent hospitalization for HF (HHF) across the spectrum of left ventricular ejection fraction (LVEF)”

“Apart from increased surveillance and monitoring, the therapeutic consequence of identifying CMP variants, particularly in asymptomatic individuals, remains unclear”

DiscussionFind in source

Randomization came from the parent double-blind, randomized, placebo-controlled trial; blinding is described (double-blind, and events adjudicated by a committee blinded to treatment assignment). Inclusion/exclusion for the genetic substudy (consent + available WES, stringent variant curation) is detailed. Outlier/missing-data handling is stated (available-case, no imputation needed). No a priori power/sample-size calculation is reported, which is typical for a post-hoc subgroup analysis. Independent replication is appropriately not claimed and a prospective trial is stated as needed.

Sub-criteria

controlsN/A

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

As a secondary analysis of a randomized double-blind trial, randomization, blinding, and the analysis population are adequately described; no a priori power calculation is reported for the substudy.

Evidence

“This is a secondary analysis of DECLARE-TIMI 58, a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

“All events were adjudicated by a central clinical events committee blinded to treatment assignment”

MethodsFind in source

“This analysis was not prespecified.”

MethodsFind in source

PASSReviewer 2· 70% conf

The parent trial was randomized, double-blind, and placebo-controlled with blinded adjudication; the genetic substudy reports inclusion/exclusion via sequencing QC and an available-case analysis with no imputation.

Evidence

“This is a secondary analysis of DECLARE-TIMI 58, a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

“All events were adjudicated by a central clinical events committee blinded to treatment assignment”

MethodsFind in source

“Analyses were performed on an available-case basis; no imputation methods were required due to minimal missing data.”

Statistical analysisFind in source

Both sexes were enrolled (male 61% carriers vs 64% noncarriers), so no single-sex justification is required. Age (63.4±6.4), BMI, comorbidities, NT-proBNP, and hs-TnT are reported. Human demographics including ethnicity are provided in Table 1 and Extended Data Tables.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Human demographic and clinical variables are thoroughly reported for carriers and noncarriers.

Evidence

“Male sex | 74 (61) | 8,051 (64) | 0.57”

Table 1Find in source

“Male sex | 74 (61) | 8,051 (64)”

Table 1Find in source

PASSReviewer 2· 95% conf

Sex, age, weight/BMI, health status, and ethnicity are all reported in baseline tables for both carriers and noncarriers.

Evidence

“| Male sex | 74 (61) | 8,051 (64) | 0.57 |”

Table 1Find in source

“| Age | 63.4 ± 6.4 | 64 ± 6.9 | 0.43 |”

Table 1Find in source

“| Ethnicity | Asian 7 (6) | Asian 1,140 (9) | 0.01 |”

Table 1Find in source

The paper states 'The trial protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent,' which adequately covers approval and consent. However, no named regulatory framework (Declaration of Helsinki, ICH-GCP) is explicitly cited, so regulatory_compliance is not reported. Because all applicable ethical elements must be adequate for a pass, this gap yields a warn.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

IRB approval and written informed consent are stated, but no explicit regulatory-compliance framework (e.g., Declaration of Helsinki) is named.

Evidence

“The trial protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent.”

MethodsFind in source

absence[Methods, Study design]

No named regulatory-compliance framework is cited.

WARNReviewer 2· 75% conf

IRB approval and written informed consent are stated, but no named regulatory-compliance framework (e.g., Declaration of Helsinki) is explicitly cited.

Evidence

“The trial protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent.”

MethodsFind in source

absence[Methods]

No named regulatory-compliance framework is cited.

Software tools are thoroughly identified (R 4.4.2, BWA 0.7.15-r1140, GATK 4.1.4.1, VEP v105, LOFTEE, with GitHub URLs). The investigational product 'dapagliflozin' is named along with the sponsor (AstraZeneca), but no dose, regimen, or formulation is given in the text, so reagents_identified is reported_but_inadequate. Antibodies, cell lines, mycoplasma, and organisms are not applicable to this clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

Analysis software is well identified, but the investigational product (dapagliflozin) is named without dose/regimen/formulation.

Evidence

paraphrase[Methods, Study design]

“Paraphrase: The agent is named as dapagliflozin in a placebo-controlled trial, but the dose, regimen, and formulation are not stated.”

“All analyses were performed using R version 4.4.2 (R Foundation).”

MethodsFind in source

WARNReviewer 2· 70% conf

Analysis software is well identified, but the investigational product (dapagliflozin) is named without dose, formulation, or manufacturer, and no sequencing data accessions are given.

Evidence

“dapagliflozin treatment”

AbstractFind in source

“All analyses were performed using R version 4.4.2 (R Foundation).”

Statistical analysisFind in source

“aligned to GRCh38 with BWA 0.7.15-r1140 and converted to SAM specification 1.6 CRAM files with GATK 4.1.4.1”

MethodsFind in source

Cox proportional-hazard models, Wilcoxon rank-sum, chi-squared, Wald tests, and Schoenfeld residuals are named; the proportional-hazards assumption was tested with no violations. HRs and ARRs are reported with 95% CIs throughout. Software (R 4.4.2) is identified. Data presentation uses KM curves with per-group n and CIs. Exact p-values are given for most comparisons (e.g., P interaction 0.03, 0.01), with thresholds (P < 0.001) used only for very small values. Checkable proportions are plausible (221/6,291 = 3.5%; 9/56 = 16%; NNT 1/0.13 = 7.7).

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are named, assumptions tested, effect sizes reported with CIs, and proportions are arithmetically plausible.

Evidence

“We tested the proportional hazards assumption using Schoenfeld residuals and found no violations.”

Statistical analysisFind in source

“dapagliflozin lowered the risk of HHF more strongly in carriers (hazard ratio 0.18, 95% confidence interval 0.04–0.86) than in noncarriers (hazard ratio 0.70, 95% confidence interval 0.57–0.86; P interaction 0.03)”

AbstractFind in source

“the incidence of HHF was 3.5% (221/6,291) in noncarriers and 16% (9/56) in carriers”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical tests, proportional-hazards assumption checking, effect sizes with confidence intervals, software, and data presentation are all adequately reported; no demonstrable arithmetic errors were found.

Evidence

“We tested the proportional hazards assumption using Schoenfeld residuals and found no violations.”

Statistical analysisFind in source

“Among CMP variant carriers, treatment with dapagliflozin resulted in an 82% reduction in incident HHF (HR 0.18, 95% CI 0.04–0.86).”

Main, Treatment effect by carrier statusFind in source

“the incidence of HHF was 3.5% (221/6,291) in noncarriers and 16% (9/56) in carriers”

Main, Association of carrier status wit…Find in source

A data-availability statement exists but offers no concrete access route, platform, or managed-access mechanism, so it is reported_but_inadequate. The study generated non-identifiable sequencing data (13,184 exomes) for which accessions would be expected but none are given. No bespoke analysis code is shared. None of the applicable availability criteria is adequate, so the dimension fails.

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

A data-availability statement explains why trial data are not shared, but no accession for the whole-exome sequencing data and no custom-code repository are provided.

Evidence

“Due to contractual agreements with sponsors, trial data are not available to share.”

Data availabilityFind in source

absence[Data availability / Methods]

No sequencing accession number is provided for the WES data.

paraphrase[Methods, Sequence data quality control]

“Paraphrase: The GATK and LOFTEE GitHub pipelines are referenced, but no repository for the study-specific analysis code is given.”

FAILReviewer 2· 60% conf

The data-availability statement is vague ('data are not available to share'), no sequencing accessions are provided for the exome data, and no analysis code is shared.

Evidence

“Due to contractual agreements with sponsors, trial data are not available to share.”

Data availabilityFind in source

absence[Methods / Data availability]

No sequencing accession numbers are provided for the exome data.

absence[Data availability / Methods]

No custom analysis code is shared.

Methods are sufficiently detailed for replication (sequencing QC, variant curation, models). DECLARE-TIMI 58 registration (NCT01730534) is given. Secondary exploratory endpoints (CV death, composite, all-cause mortality) are reported as non-significant. The limitations section is extensive and conclusions are appropriately hedged ('hypothesis-generating', 'need to be confirmed in a prospective, dedicated trial'). Funding and competing interests are detailed. The reporting guideline is referenced only via a linked 'Reporting summary' rather than an explicitly named checklist, which is a minor gap that does not prevent a pass.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Methods are detailed, the parent trial is registered, negative secondary endpoints are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

paraphrase[Funding]

“DECLARE-TIMI 58 ( NCT01730534 ) was funded by AstraZeneca.”

“These results need to be confirmed in a prospective, dedicated trial of preventive HF treatments in carriers of P/LP cardiomyopathy-associated variants.”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

PASSReviewer 2· 80% conf

Methods are detailed, the parent trial is registered, negative secondary endpoints are reported, limitations are thoroughly discussed, conclusions are appropriately hedged, and funding/COI statements are provided.

Evidence

paraphrase[Funding]

“DECLARE-TIMI 58 ( NCT01730534 )”

“These results need to be confirmed in a prospective, dedicated trial of preventive HF treatments”

AbstractFind in source

“Another important limitation of this analysis is the absence of systematic cardiac imaging.”

DiscussionFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 30 references by DOI: 5 verified — 25 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

4 copyedit issues flagged (2 major): mostly consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

In a post-publication audit, the published work is methodologically sound in its core randomized comparison and self-consciously hypothesis-generating; an informed reader should weigh the small carrier subgroup (9 placebo events; wide HR CI 0.04–0.86; interaction p=0.03), the absence of sequencing data accessions and analysis code, and the main-text ARR CI typo (missing minus sign), which is a minor internal inconsistency that would warrant a small erratum rather than re-analysis. No recomputed statistical error was found, and the headline interaction finding is appropriately hedged.

1.
HIGHcopyedit
Correct the missing minus sign in the Results text for carriers with prior HF — change '17.9% (95% CI 20.6–56.5%)' to '17.9% (95% CI −20.6% to 56.5%)' to match Fig. 3b and so the CI brackets the point estimate.
This is a demonstrable internal contradiction between the main text and figure caption (also flagged by the integrity lens) that an informed reader will notice and which warrants an erratum.
2.
HIGHdata code
Provide a concrete access route for the whole-exome sequencing data (13,184 exomes) — e.g., deposit in a controlled-access repository (dbGaP/EGA) with accession numbers, or name a managed-access committee with request conditions — in the Data availability section.
Generated sequencing data are a key reproducibility resource; the absence of any accession leaves the substudy's core data effectively unavailable to readers.
3.
HIGHdata code
Deposit the study-specific analysis code (variant curation and the Cox/pseudo-value modeling) in a version-controlled public repository with a persistent identifier and cite it in Methods, Statistical analysis.
Only third-party pipeline URLs (GATK, LOFTEE) are cited; the custom analysis code is not shared, limiting independent re-analysis of the subgroup interaction.
4.
MEDIUMethics
Add an explicit regulatory-compliance statement (e.g., 'conducted in accordance with the Declaration of Helsinki' / ICH-GCP) to the Methods ethics paragraph alongside the IRB approval statement.
IRB approval and consent are stated but no named compliance framework is given, which is the sole reason the ethics dimension does not pass.
5.
MEDIUMrigor
State the dapagliflozin dose, regimen, formulation, and manufacturer in Methods, Study design (the parent DECLARE-TIMI 58 dose was 10 mg).
The investigational product is the key resource in a drug trial and is currently named without dose/formulation, so the intervention cannot be fully reproduced from the text.
6.
MEDIUMreporting
Cite a named reporting guideline (e.g., STROBE for the observational genetic analysis, or CONSORT for the parent trial) instead of only the generic linked 'Reporting summary'.
A named checklist is the current reporting-guideline gap in an otherwise transparent methods section.
7.
MEDIUMcopyedit
Reconcile the NT-proBNP p-value between the main text ('P < 0.001') and Table 1 ('0.0004') so a single value is used.
Both values indicate strong significance, but the inconsistency is a minor internal-consistency issue a reader or editor will catch.
8.
MEDIUMrigor
Keep the small-event basis of the carrier-subgroup finding prominent: the treatment-effect interaction rests on 9 placebo events in 56 carriers (HR 0.18, 95% CI 0.04–0.86; interaction p=0.03) and should remain framed as hypothesis-generating.
The wide CI and borderline interaction p make this a hypothesis-generating signal, not a demonstration of benefit; the authors already acknowledge this and it should stay foregrounded.
9.
LOWstatistics
Where feasible, report exact p-values instead of thresholds (e.g., the overall HHF HR and the aHR 8.06 reported as 'P < 0.001').
Threshold-only reporting of a computed p-value is imprecise; exact values improve precision while remaining consistent with the current conclusions.
10.
LOWcopyedit
Remove the duplicated data-availability sentence that appears in both 'Data availability' and 'Associated Data' so the statement appears once.
The identical sentence is stated twice, a minor redundancy in the published layout.

Full text (43,703 chars)Analyzed: Aug 10, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Marston NA, Kany S, Melloni GEM, Jurgens SJ, Kamanu FK, Lai YP, Rämö JT, Raz I, Wiviott SD, Ellinor PT, Sabatine MS, Ruff CT

Read full text (PMC)

DOI

10.1038/s41591-026-04439-x

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b0bd815e-ed54-4cf8-a026-845a008ff135" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b0bd815e-ed54-4cf8-a026-845a008ff135/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 3 high issues for “Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4a4ce306bfa73364a3e5aa68d73762bdcb3ccc272c5823f3698370583b959f8f

Verify via API

Issued Aug 10, 2026Engine 7.29.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Biggest issues

01Data and code not shared
highDisclosurereviewer-assessedFull detail
The data-availability statement is vague ('data are not available to share'), no sequencing accessions are provided for the exome data, and no analysis code is shared.
“Due to contractual agreements with sponsors, trial data are not available to share.”
Data availabilityFind in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 05AvailabilityNone found 106CopyeditCopyediting

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 12 tests: 12 consistent, 0 inconsistent; 6 recomputed directly from the reported test statistics, 6 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

Implausibly large reported effectAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

3 findings · worst high

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Eight Dimensions5 pass · 2 warn · 1 fail

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The scientific foundation is well established and the rationale follows clearly from prior evidence.

Evidence

Main, first two paragraphsFind in source

“Whether SGLT2 inhibitor treatment is of benefit in asymptomatic individuals with a CMP variant is not known.”

IntroductionFind in source

paraphrase[Discussion, final paragraphs]

“Paraphrase: The authors enumerate small carrier number (n=121), the post-hoc nature, absence of systematic cardiac imaging, short follow-up, and limited ancestry diversity as limitations.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific rationale grounded in prior work on SGLT2 inhibitors in heart failure and on the prognostic significance of cardiomyopathy variants.

Evidence

“Whether SGLT2 inhibitor treatment is of benefit in asymptomatic individuals with a CMP variant is not known.”

Main, paragraph 1Find in source

paraphrase[Main, paragraph 1]

“SGLT2 inhibitors such as dapagliflozin have been shown to prevent hospitalization for HF (HHF) across the spectrum of left ventricular ejection fraction (LVEF)”

“Apart from increased surveillance and monitoring, the therapeutic consequence of identifying CMP variants, particularly in asymptomatic individuals, remains unclear”

DiscussionFind in source

Sub-criteria

controlsN/A

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

As a secondary analysis of a randomized double-blind trial, randomization, blinding, and the analysis population are adequately described; no a priori power calculation is reported for the substudy.

Evidence

“This is a secondary analysis of DECLARE-TIMI 58, a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

“All events were adjudicated by a central clinical events committee blinded to treatment assignment”

MethodsFind in source

“This analysis was not prespecified.”

MethodsFind in source

PASSReviewer 2· 70% conf

Evidence

“This is a secondary analysis of DECLARE-TIMI 58, a double-blind, randomized, placebo-controlled trial”

MethodsFind in source

“All events were adjudicated by a central clinical events committee blinded to treatment assignment”

MethodsFind in source

“Analyses were performed on an available-case basis; no imputation methods were required due to minimal missing data.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Human demographic and clinical variables are thoroughly reported for carriers and noncarriers.

Evidence

“Male sex | 74 (61) | 8,051 (64) | 0.57”

Table 1Find in source

“Male sex | 74 (61) | 8,051 (64)”

Table 1Find in source

PASSReviewer 2· 95% conf

Sex, age, weight/BMI, health status, and ethnicity are all reported in baseline tables for both carriers and noncarriers.

Evidence

“| Male sex | 74 (61) | 8,051 (64) | 0.57 |”

Table 1Find in source

“| Age | 63.4 ± 6.4 | 64 ± 6.9 | 0.43 |”

Table 1Find in source

“| Ethnicity | Asian 7 (6) | Asian 1,140 (9) | 0.01 |”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

IRB approval and written informed consent are stated, but no explicit regulatory-compliance framework (e.g., Declaration of Helsinki) is named.

Evidence

“The trial protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent.”

MethodsFind in source

absence[Methods, Study design]

No named regulatory-compliance framework is cited.

WARNReviewer 2· 75% conf

IRB approval and written informed consent are stated, but no named regulatory-compliance framework (e.g., Declaration of Helsinki) is explicitly cited.

Evidence

“The trial protocol was approved by the institutional review board at each participating site, and all participants provided written informed consent.”

MethodsFind in source

absence[Methods]

No named regulatory-compliance framework is cited.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

Analysis software is well identified, but the investigational product (dapagliflozin) is named without dose/regimen/formulation.

Evidence

paraphrase[Methods, Study design]

“Paraphrase: The agent is named as dapagliflozin in a placebo-controlled trial, but the dose, regimen, and formulation are not stated.”

“All analyses were performed using R version 4.4.2 (R Foundation).”

MethodsFind in source

WARNReviewer 2· 70% conf

Analysis software is well identified, but the investigational product (dapagliflozin) is named without dose, formulation, or manufacturer, and no sequencing data accessions are given.

Evidence

“dapagliflozin treatment”

AbstractFind in source

“All analyses were performed using R version 4.4.2 (R Foundation).”

Statistical analysisFind in source

“aligned to GRCh38 with BWA 0.7.15-r1140 and converted to SAM specification 1.6 CRAM files with GATK 4.1.4.1”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are named, assumptions tested, effect sizes reported with CIs, and proportions are arithmetically plausible.

Evidence

“We tested the proportional hazards assumption using Schoenfeld residuals and found no violations.”

Statistical analysisFind in source

AbstractFind in source

“the incidence of HHF was 3.5% (221/6,291) in noncarriers and 16% (9/56) in carriers”

ResultsFind in source

PASSReviewer 2· 80% conf

Evidence

“We tested the proportional hazards assumption using Schoenfeld residuals and found no violations.”

Statistical analysisFind in source

“Among CMP variant carriers, treatment with dapagliflozin resulted in an 82% reduction in incident HHF (HR 0.18, 95% CI 0.04–0.86).”

Main, Treatment effect by carrier statusFind in source

“the incidence of HHF was 3.5% (221/6,291) in noncarriers and 16% (9/56) in carriers”

Main, Association of carrier status wit…Find in source

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 70% conf

A data-availability statement explains why trial data are not shared, but no accession for the whole-exome sequencing data and no custom-code repository are provided.

Evidence

“Due to contractual agreements with sponsors, trial data are not available to share.”

Data availabilityFind in source

absence[Data availability / Methods]

No sequencing accession number is provided for the WES data.

paraphrase[Methods, Sequence data quality control]

“Paraphrase: The GATK and LOFTEE GitHub pipelines are referenced, but no repository for the study-specific analysis code is given.”

FAILReviewer 2· 60% conf

The data-availability statement is vague ('data are not available to share'), no sequencing accessions are provided for the exome data, and no analysis code is shared.

Evidence

“Due to contractual agreements with sponsors, trial data are not available to share.”

Data availabilityFind in source

absence[Methods / Data availability]

No sequencing accession numbers are provided for the exome data.

absence[Data availability / Methods]

No custom analysis code is shared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Methods are detailed, the parent trial is registered, negative secondary endpoints are reported, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

paraphrase[Funding]

“DECLARE-TIMI 58 ( NCT01730534 ) was funded by AstraZeneca.”

“These results need to be confirmed in a prospective, dedicated trial of preventive HF treatments in carriers of P/LP cardiomyopathy-associated variants.”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

PASSReviewer 2· 80% conf

Evidence

paraphrase[Funding]

“DECLARE-TIMI 58 ( NCT01730534 )”

“These results need to be confirmed in a prospective, dedicated trial of preventive HF treatments”

AbstractFind in source

“Another important limitation of this analysis is the absence of systematic cardiac imaging.”

DiscussionFind in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 30 references by DOI: 5 verified — 25 no DOI (shown, not verified).

4 data/code links checked; 4 live.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

4 copyedit issues flagged (2 major): mostly consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
Correct the missing minus sign in the Results text for carriers with prior HF — change '17.9% (95% CI 20.6–56.5%)' to '17.9% (95% CI −20.6% to 56.5%)' to match Fig. 3b and so the CI brackets the point estimate.
This is a demonstrable internal contradiction between the main text and figure caption (also flagged by the integrity lens) that an informed reader will notice and which warrants an erratum.
2.
HIGHdata code
Provide a concrete access route for the whole-exome sequencing data (13,184 exomes) — e.g., deposit in a controlled-access repository (dbGaP/EGA) with accession numbers, or name a managed-access committee with request conditions — in the Data availability section.
Generated sequencing data are a key reproducibility resource; the absence of any accession leaves the substudy's core data effectively unavailable to readers.
3.
HIGHdata code
Deposit the study-specific analysis code (variant curation and the Cox/pseudo-value modeling) in a version-controlled public repository with a persistent identifier and cite it in Methods, Statistical analysis.
Only third-party pipeline URLs (GATK, LOFTEE) are cited; the custom analysis code is not shared, limiting independent re-analysis of the subgroup interaction.
4.
MEDIUMethics
Add an explicit regulatory-compliance statement (e.g., 'conducted in accordance with the Declaration of Helsinki' / ICH-GCP) to the Methods ethics paragraph alongside the IRB approval statement.
IRB approval and consent are stated but no named compliance framework is given, which is the sole reason the ethics dimension does not pass.
5.
MEDIUMrigor
State the dapagliflozin dose, regimen, formulation, and manufacturer in Methods, Study design (the parent DECLARE-TIMI 58 dose was 10 mg).
The investigational product is the key resource in a drug trial and is currently named without dose/formulation, so the intervention cannot be fully reproduced from the text.
6.
MEDIUMreporting
Cite a named reporting guideline (e.g., STROBE for the observational genetic analysis, or CONSORT for the parent trial) instead of only the generic linked 'Reporting summary'.
A named checklist is the current reporting-guideline gap in an otherwise transparent methods section.
7.
MEDIUMcopyedit
Reconcile the NT-proBNP p-value between the main text ('P < 0.001') and Table 1 ('0.0004') so a single value is used.
Both values indicate strong significance, but the inconsistency is a minor internal-consistency issue a reader or editor will catch.
8.
MEDIUMrigor
Keep the small-event basis of the carrier-subgroup finding prominent: the treatment-effect interaction rests on 9 placebo events in 56 carriers (HR 0.18, 95% CI 0.04–0.86; interaction p=0.03) and should remain framed as hypothesis-generating.
The wide CI and borderline interaction p make this a hypothesis-generating signal, not a demonstration of benefit; the authors already acknowledge this and it should stay foregrounded.
9.
LOWstatistics
Where feasible, report exact p-values instead of thresholds (e.g., the overall HHF HR and the aHR 8.06 reported as 'P < 0.001').
Threshold-only reporting of a computed p-value is imprecise; exact values improve precision while remaining consistent with the current conclusions.
10.
LOWcopyedit
Remove the duplicated data-availability sentence that appears in both 'Data availability' and 'Associated Data' so the statement appears once.
The identical sentence is stated twice, a minor redundancy in the published layout.

Full text (43,703 chars)Analyzed: Aug 10, 2026